Pasithea Therapeutics Confirms Receipt Of Unsolicited Proposal From Lucy Scientific Discovery; Per Share Consideration Consists Of $0.60 In Cash Plus $0.25 Worth Of Lucy Common Stock
Portfolio Pulse from Benzinga Newsdesk
Pasithea Therapeutics has received an unsolicited proposal from Lucy Scientific Discovery to acquire all outstanding shares of Pasithea common stock for $0.60 in cash plus $0.25 worth of Lucy common stock per share.
June 06, 2023 | 8:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pasithea Therapeutics may be acquired by Lucy Scientific Discovery, with shareholders receiving $0.60 in cash and $0.25 worth of Lucy common stock per share.
The unsolicited proposal from Lucy Scientific Discovery to acquire Pasithea Therapeutics could lead to a potential merger or acquisition, which may positively impact Pasithea's stock price in the short term. Shareholders would receive a combination of cash and Lucy common stock, making the deal attractive.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Lucy Scientific Discovery has made an unsolicited proposal to acquire Pasithea Therapeutics, offering $0.60 in cash and $0.25 worth of Lucy common stock per share.
The unsolicited proposal to acquire Pasithea Therapeutics indicates Lucy Scientific Discovery's interest in expanding its business and portfolio. If the acquisition is successful, it could positively impact Lucy's stock price in the short term as it may lead to potential synergies and growth opportunities.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100